GlaxoSmithKline News and Research

RSS

VivoMetrics receives US patent for cough identification system

VivoMetrics has announced that the United States Patent Office has granted the company a new patent for its cough identification system algorithm.

1 May 2007

More effective therapies for individual cancers - personalized medicine

Genetic and epigenetic variations ensure that no two people are exactly alike, and the same holds true for any two cancers.

18 Apr 2007

Taking a jab at cancer by stimulating the immune system

As the first FDA-approved cancer vaccine, designed to protect against human papillomavirus, has moved from scientific discussion to social debate, other vaccine studies are continuing to make progress.

18 Apr 2007

GlaxoSmithKline initiates study of PROMACTA in chronic idiopathic thrombocytopenic purpura

GlaxoSmithKline has announced the initiation of a global, open-label, single group trial that will assess the efficacy, safety and tolerability of PROMACTA (eltrombopag olamine) in patients previously treated for chronic idiopathic thrombocytopenic purpura (ITP).

15 Apr 2007

Coley Pharmaceutical licenses VaxImmune to Merck

Coley Pharmaceutical Group has announced that Merck & Co has licensed Coley's VaxImmune vaccine adjuvant for incorporation into vaccines being developed by Merck for certain infectious diseases and Alzheimer's disease.

15 Apr 2007

FDA approves GlaxoSmithKline's antibacterial Altabax

GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has approved its antibacterial Altabax for the topical treatment of impetigo due to susceptible strains of Staphylococcus aureus or Streptococcus pyogenes, the two most common types of bacteria in this kind of infection.

14 Apr 2007

FDA approves Altabax ointment for impetigo

The Food and Drug Administration (FDA) approved Altabax (retapamulin ointment) for topical treatment of impetigo, a skin infection caused by bacteria.

14 Apr 2007

Report reveals cost of type 2 diabetes complications

A first-of-its-kind report looking at the prevalence and cost of type 2 diabetes complications shows that an estimated three out of five people (57.9 percent) with type 2 diabetes have at least one of the other serious health problems commonly associated with the disease, and that these health problems are taking a heavy financial toll on the United States.

11 Apr 2007

FDA approves Twinrix

GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has approved Twinrix [Hepatitis A Vaccine (Inactivated) and Hepatitis B (Recombinant) Vaccine], for an accelerated dosing schedule that consists of three doses given within three weeks followed by a booster dose at 12 months.

4 Apr 2007

GlaxoSmithKline submits Biologics License Application (BLA) for CERVARIX

If licensed, the vaccine will be indicated for the prevention of cervical cancer and precancerous lesions associated with the most common cancer-causing human papillomavirus types.

1 Apr 2007

GlaxoSmithKline files European meningococcal conjugate vaccine

GlaxoSmithKline has announced the submission of a regulatory file to European Medicines Agency (EMEA) under Article 58 for the combination vaccine candidate Globorix (diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, Neisseria meningitides serogroups A and C).

1 Apr 2007

HPV vaccine proposals in Florida, Georgia, North Carolina, South Dakota

Merck's HPV vaccine Gardasil and GlaxoSmithKline's HPV vaccine Cervarix in clinical trials have been shown to be 100% effective in preventing infection with HPV strains 16 and 18, which together cause about 70% of cervical cancer cases.

22 Mar 2007

Canada budgets $258 million for human papillomavirus vaccination programs

The Canadian government on Monday announced that it is including about $258 million in the 2007-2008 budget to help pay for provincial human papillomavirus vaccination programs, Toronto's Globe and Mail reports.

22 Mar 2007

Pioneer work on cellular response to DNA Damage wins GlaxoSmithKline award

The Biochemical Society's GlaxoSmithKline Award 'for distinguished research leading to new advances in medical science' goes to Stephen Jackson (University of Cambridge) for his pioneering work on cellular response to DNA damage.

22 Mar 2007

Tykerb (lapatinib) - new anti-cancer treatment approved

The Food and Drug Administration (FDA) has approved Tykerb (lapatinib), a new targeted anti-cancer treatment, to be used in combination with capectabine (Xeloda), another cancer drug, for patients with advanced, metastatic breast cancer that is HER2 positive (tumors that exhibit HER2 protein).

14 Mar 2007

Bird flu vaccine - experts say let's try harder

Experts on viruses are calling for a bigger effort to be made in developing vaccines to tackle pandemics.

6 Mar 2007

Safety of Merck's HPV vaccine Gardasil 'lost' in debate

The effectiveness and safety of Merck's human papillomavirus vaccine Gardasil has "been lost" because of Merck's lobbying campaign for mandating vaccination for school attendance, and the "real losers" might be "girls and women who need access" to the vaccine, Boston Globe columnist Ellen Goodman writes in an opinion piece .

5 Mar 2007

Actions taken on HPV vaccine proposals in Kentucky, Massachusetts, New Mexico, Ohio, South Dakota and Virginia

4 Mar 2007

Lawmakers should not make HPV vaccination mandatory, CDC advisory panel chair says

Jon Abramson, chair of CDC's Advisory Committee on Immunization Practices, recently said that he does not support mandating human papillomavirus vaccination for school attendance, the Washington Times reports.

1 Mar 2007

State actions on human papillomavirus vaccine proposals

The following highlights recent news of state actions on human papillomavirus vaccine proposals. Merck's HPV vaccine Gardasil and GlaxoSmithKline's HPV vaccine Cervarix in clinical trials have been shown to be 100% effective in preventing infection with HPV strains 16 and 18, which together cause about 70% of cervical cancer cases.

25 Feb 2007